• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Weight loss: GI Dynamics: U.S. clinical trial on tap for this year

Weight loss: GI Dynamics: U.S. clinical trial on tap for this year

March 1, 2012 By MassDevice staff

GI Dynamics

GI Dynamics (ASX:GID), in its first earnings release as a publicly traded firm, said it’s hoping to start a U.S. clinical trial of its EndoBarrier weight-loss and diabetes device this year.

The Lexington, Mass.-based company posted losses of $26.4 million, or $1.29 per share, on sales of $234,000 for the year ended Dec. 31, 2011.

GI Dynamics went public in September 2011, netting nearly $80 million (A$74 million) in an initial public offering on the Australian stock exchange. The company said it had about $66 million in the bank at the end of the year.

Sign up to get our free newsletters delivered straight to your inbox

“In the United States, the company is engaged in conversations with the FDA to further define its U.S. clinical program. Following the conclusion of these conversations, the company expects to begin a clinical study of the EndoBarrier in the U.S. later this year,” according to a press release.

CEO Stuart Randle said the company is focused on adding to its roster of “Centers of Excellence” for the EndoBarrier procedure.

“Having established a solid commercial foundation in 2011 upon which to build, we are well positioned to continue to advance our sales and business objectives in 2012 and expect to have approximately 30 Centers of Excellence established by year-end,” Randle said in prepared remarks.

The EndoBarrier is a plastic gut-lining sleeve that hangs from the outlet of the stomach and lines the small intestine. It’s designed to slow the uptake of nutrients to effect weight loss, and has been shown in small clinical trials to also mitigate the symptoms of diabetes. It’s on the market in the U.K., Netherlands, Austria, Germany and Chile; GI Dynamics said it’s planning to begin sales in “a select number of new countries,” including Australia, some time in 2012.

Filed Under: MassDevice Earnings Roundup, News Well, Wall Street Beat, Weight loss Tagged With: Bariatrics, GI Dynamics, Q4

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy